{"id":"W2945661283","doi":"10.1200/jco.19.00315","title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Dacarbazine; Adverse effect; Neutropenia; Clinical endpoint; Tolerability; Rash; Oncology; Surgery; Cancer; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003656746,0.000204065,0.001704742,0.0001112236,0.00008643019,0.00001636448,0.0002047402,0.0002401372,0.00009649243],"category_scores_gemma":[0.002515336,0.0001153432,0.0004197076,0.0001507776,0.000120763,0.0001253262,0.00007395806,0.0003359856,0.00001205569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002940984,"about_ca_system_score_gemma":0.0008573591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003394136,"about_ca_topic_score_gemma":0.000122413,"domain_scores_codex":[0.9964218,0.000485935,0.002144543,0.0002996094,0.0003374336,0.0003106353],"domain_scores_gemma":[0.9904756,0.007561602,0.001228045,0.0003186418,0.0001729278,0.0002431963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.026371,0.06983307,0.1132356,0.00004075278,0.0005510481,0.001720516,0.00102591,0.00003951235,0.00003837027,0.0003490237,0.002113531,0.7846816],"study_design_scores_gemma":[0.2248933,0.08504176,0.5792916,0.00008723456,0.0004520846,0.0001405127,0.001018258,0.0001552957,0.00001288212,0.00009064213,0.1087134,0.0001031064],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896289,0.0007859219,0.00002418486,0.006186897,0.0007985705,0.001757817,0.00001236,0.000007683936,0.0007977028],"genre_scores_gemma":[0.9952899,0.001019469,0.0007288427,0.002129289,0.0003750054,0.00004018405,0.000005167553,0.00001945249,0.0003927202],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7845785,"threshold_uncertainty_score":0.470356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07774469496044747,"score_gpt":0.4610485409977395,"score_spread":0.383303846037292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}